Back to top
Read MoreHide Full Article

Facebook Inc. (FB - Free Report) , operates a social networking website worldwide. This Zacks Rank #1, Strong Buy, stock with a Growth score of ‘A’, has ample growth catalysts. Not the least of which are earnings estimates that continue to rise. A strong balance sheet and significant cash flow also make it attractive for investors. 

Vertex Pharmaceuticals Inc. (VRTX - Free Report) , discovers, develops and markets small molecule drugs that address major unmet medical needs.  This company has two cystic fibrosis drugs in its portfolio with blockbuster potential. The company also has a strong history of beating consensus earnings estimates. It’s not only a Zacks Rank #1, Strong Buy, but has both Growth and Momentum scores of ‘A’.

More Stock News: Tech Opportunity Worth $386 Billion in 2017

From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.                                                                                

Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Facebook, Inc. (FB) - free report >>

Vertex Pharmaceuticals Incorporated (VRTX) - free report >>


More from Zacks Video Blog

You May Like